iRhythm Holdings, Inc. (IRTC)
| Market Cap | 4.09B |
| Revenue (ttm) | 747.14M |
| Net Income (ttm) | -44.55M |
| Shares Out | 32.62M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 477,282 |
| Open | 126.38 |
| Previous Close | 125.96 |
| Day's Range | 123.87 - 128.21 |
| 52-Week Range | 104.53 - 212.00 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 197.92 (+57.82%) |
| Earnings Date | Apr 30, 2026 |
About IRTC
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IRTC stock is "Strong Buy." The 12-month stock price target is $197.92, which is an increase of 57.82% from the latest price.
News
New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio ® ...
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict di...
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio ® ambulatory ECG portfolio. 1,2 Chief Medical Officer Mintu Tur...
iRhythm Holdings Appoints Jason Patten to its Board of Directors
SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent d...
iRhythm Holdings Earnings Call Transcript: Q4 2025
Delivered record 2025 revenue growth of 26%, first-ever positive net income and free cash flow, and expanded margins, driven by strong volume across all channels and operational efficiencies. 2026 guidance calls for 16–18% revenue growth and further margin expansion.
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent di...
iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict dis...
HALPER SADEH LLC ENCOURAGES IRHYTHM TECHNOLOGIES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Halper Sadeh LLC Encourages iRhythm Technologies, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary ...
iRhythm Tech's Stock Selloff Went Too Far After Preliminary Update: Analyst
On Monday, iRhythm Technologies Inc. (NASDAQ: IRTC) reported preliminary fourth quarter operational highlights.
iRhythm Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Proactive arrhythmia detection and AI-driven predictive tools are expanding market reach, with strong growth in primary care and international markets. Record 2025 revenue and profitability set the stage for 17–18% growth in 2026, supported by new product launches and operational efficiencies.
iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent ...
iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent...
iRhythm Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
Cardiac monitoring solutions are driving strong growth, with revenue acceleration in 2025 fueled by product innovation, EHR integration, and proactive monitoring channels. Favorable reimbursement trends and a robust product pipeline support a positive outlook, with margin expansion and new market opportunities ahead.
iRhythm Holdings Transcript: Citi Annual Global Healthcare Conference 2025
Ambulatory cardiac monitoring is experiencing robust growth, driven by primary care adoption, workflow innovation, and proactive risk-based partnerships. International expansion and product innovation, including AI and multi-vitals platforms, are set to drive future growth, with profitability and revenue guidance reflecting a balanced, data-driven approach.
iRhythm Holdings Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted strong revenue growth, expanding market share, and robust international expansion, driven by innovative AI-powered cardiac monitoring solutions. Strategic partnerships, EHR integration, and a multivitals platform underpin future growth and profitability.
iRhythm Holdings Transcript: Wolfe Research Healthcare Conference 2025
Management addressed draft LCD concerns, reaffirmed confidence in regulatory outcomes, and highlighted strong 2025 growth driven by XT, AT, and innovative channel partners. Next-gen MCT is on track for a 2026 launch, and international expansion efforts focus on Japan despite reimbursement hurdles.
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of iRhythm Technologies, Inc. – IRTC
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of iRhythm Technologies...
iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025
New Heart Rhythm Journal publication and AHA 2025 data reinforce Zio LTCM clinical value and real-world evidence supporting proactive cardiac monitoring.
iRhythm: The Heart Monitor Maker Whose Stock Keeps Beating
iRhythm Technologies stock has doubled this year.
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict...
iRhythm Well-Positioned For 2026 After Upbeat Results And Raised Outlook
iRhythm Technologies Inc. (NASDAQ:IRTC) reported a third-quarter loss of 6 cents per share on Thursday, better than analysts' expectation of a 31-cent loss.
iRhythm Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw 31% revenue growth, record Zio Monitor and AT performance, and improved profitability, with raised full-year guidance and positive free cash flow expected. EHR integration, innovative channels, and international expansion fueled momentum, while FDA remediation and MCT approval remain key uncertainties.
iRhythm Technologies Announces Third Quarter 2025 Financial Results
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and preven...